ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Treatment of Male Sexual Partners of Women With Bacterial Vaginosis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02209519 (Randomized Controlled Trial of Treatment of Male Partners of Women With BV), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial of Treatment of Male Partners of Women With BV
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial.Cell host & microbe · 2026Trial
- EBM BLS: Male Partner Treatment Decreases Risk of Recurrent Bacterial Vaginosis in the Female Partner.Journal of general internal medicine · 2026Article
- Advances in treating bacterial vaginosis: recognizing sexual transmission and pipeline of therapies.Current opinion in infectious diseases · 2026Review
- Randomized trial of multi-strainContemporary clinical trials communications · 2025Article
- Bacterial vaginosis: an overlooked STI?Expert review of anti-infective therapy · 2025Review
- Microbiota effects and predictors ofmedRxiv : the preprint server for health sciences · 2025Article
- Bacterial vaginosis.Nature reviews. Disease primers · 2025Review
- Getting Everyone on Board to Break the Cycle of Bacterial Vaginosis (BV) Recurrence: A Qualitative Study of Partner Treatment for BV.The patient · 2025Article
- Vaginal Microbiome: Environmental, Biological, and Racial Influences on Gynecological Health Across the Lifespan.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024Review
- Article
- Sexual transmission of urogenital bacteria: whole metagenome sequencing evidence from a sexual network study.mSphere · 2024Article
- VaginalbioRxiv : the preprint server for biology · 2023Article
- Relationship between Bacterial Vaginosis and Sexually Transmitted Infections: Coincidence, Consequence or Co-Transmission?Microorganisms · 2023Article
- Sexual behavior shapes male genitourinary microbiome composition.Cell reports. Medicine · 2023Article
- Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians.International journal of women's health · 2023Review
- The Effects of Medical Male Circumcision on Female Partners' Sexual and Reproductive Health.Current HIV/AIDS reports · 2022Review
- The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation.Nature microbiology · 2022Article
- Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment.BMC medicine · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWe aimed to determine if treatment of male sexual partners of women with recurrent bacterial vaginosis (BV) with oral metronidazole 2×/day for 7 days (ie, multidose metronidazole) significantly decreased BV recurrence rates in the female.
methodsThis was a multicenter, 2-arm, double-blind, placebo-controlled study. Women with recurrent BV and current diagnosis of BV by Amsel and Nugent were enrolled. Multidose metronidazole for 7 days was dispensed to women. Male partners were randomized to placebo versus multidose metronidazole for 7 days and asked to refrain from unprotected sex for 14 days. Female follow-up visits were conducted at day 21 and 8 and 16 weeks. Male follow-up visits occurred at days 14-21. BV cure was defined as 0-2 Amsel criteria and Nugent score 0-6 in the female partner with the primary endpoint at 16 weeks.
results214 couples were enrolled. In the intent-to-treat population, there was no significant difference between treatment arms for the primary outcome. BV treatment failure occurred in 81% and 80% of women in the metronidazole and placebo arms through the third follow-up visit, respectively (P > .999). However, women whose male partners adhered to study medication were less likely to fail treatment (adjusted relative risk, .85; 95% CI, .73-.99; P = .035). This finding persisted in post hoc comparisons in the metronidazole arm.
conclusionsOverall, this study did not find that male partner treatment with multidose metronidazole significantly reduces BV recurrence in female partners, although women whose partners adhered to multidose metronidazole were less likely to fail treatment. CLINICAL TRIALS REGISTRATION: (NCT02209519).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.